Story perspectives

Bristol Myers’ arlo-cel hits high response rate in trial

9/8/2026

Summary

Story summary

Bristol Myers Squibb said its experimental CAR-T therapy arlo-cel achieved a high overall response rate in a mid-stage trial.
The trial enrolled advanced multiple myeloma patients who had exhausted four major classes of standard therapies.
A key secondary endpoint was met, with some patients showing complete clearance of detectable cancer signs.
Full results will be presented at an upcoming medical meeting, and the therapy’s safety profile matched expectations.

1 of 1

Story summary

Bristol Myers Squibb said its experimental CAR-T therapy arlo-cel achieved a high overall response rate in a mid-stage trial.
The trial enrolled advanced multiple myeloma patients who had exhausted four major classes of standard therapies.
A key secondary endpoint was met, with some patients showing complete clearance of detectable cancer signs.
Full results will be presented at an upcoming medical meeting, and the therapy’s safety profile matched expectations.